Clinic
Mckee Medical Center
Mckee Medical Center was paid $8.20M by Medicaid between Jan 2018 and Dec 2024, across 91 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoMCKEE MEDICAL CENTER
LOVELAND, CO 80538
LOVELAND, CO 80538
33aNPI1417980566assigned 07/09/2006
33bProvider typeClinic/Center
28Total paid$8.20M
24GClaims210,561
24DCodes billed91
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Colorado
Rank by total paid#7 of 87
Median peer was paid$179K
This provider vs. median46×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,264 | $1.04M | |
| 2019 | 30,786 | $1.03M | |
| 2020 | 25,664 | $1.00M | |
| 2021 | 50,528 | $1.87M | |
| 2022 | 38,565 | $1.37M | |
| 2023 | 25,421 | $1.15M | |
| 2024incomplete | 15,333 | $740K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 19,729 | 18,296 | $2.37M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 16,795 | 15,801 | $2.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.5% | 5,026 | 4,563 | $614K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.0% | 6,453 | 5,274 | $412K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.8% | 6,052 | 5,736 | $390K |
| 80053 | Comprehensive metabolic panel | 4.0% | 20,673 | 18,768 | $332K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.8% | 1,271 | 1,192 | $315K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 2,879 | 2,730 | $286K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.8% | 4,192 | 4,028 | $230K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.5% | 7,073 | 6,595 | $203K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.9% | 4,177 | 4,015 | $160K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.7% | 7,071 | 5,861 | $141K |
79 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 26,974 | $76K |
| 87081 | <1% | 3,376 | $68K | |
| 87631 | <1% | 1,010 | $67K | |
| 87653 | <1% | 1,094 | $65K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,323 | $35K |
| 87510 | <1% | 655 | $28K | |
| 87077 | <1% | 1,895 | $24K | |
| 87480 | <1% | 655 | $18K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 306 | $18K |
| 87632 | <1% | 252 | $16K | |
| 80320 | <1% | 304 | $16K | |
| 87505 | <1% | 244 | $15K | |
| 87660 | <1% | 655 | $14K | |
| 87070 | <1% | 490 | $12K | |
| 87186 | <1% | 1,998 | $10K | |
| J3490 | Unclassified drugs | <1% | 6,019 | $8K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 40 | $8K |
| 87147 | <1% | 1,002 | $6K | |
| 81001 | <1% | 2,995 | $5K | |
| 84484 | <1% | 459 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $4K |
| 87088 | <1% | 445 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,527 | $4K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 53 | $3K |
| 87177 | <1% | 85 | $3K | |
| 86769 | <1% | 62 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 57 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 54 | $2K |
| 87209 | <1% | 85 | $2K | |
| 87205 | <1% | 240 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 524 | $2K |
| 87506 | <1% | 15 | $1K | |
| 83605 | <1% | 46 | $1K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,808 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 150 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,640 | $1K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $1K |
| 81003 | <1% | 751 | $959.44 | |
| 87449 | <1% | 53 | $958.09 | |
| 84439 | <1% | 133 | $923.19 | |
| 80061 | Lipid panel | <1% | 126 | $688.68 |
| 36415 | Collection of venous blood by venipuncture | <1% | 128 | $574.72 |
| 87075 | <1% | 12 | $536.98 | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,209 | $452.83 |
| 83735 | <1% | 383 | $418.07 | |
| 87324 | <1% | 53 | $417.77 | |
| 86140 | <1% | 35 | $343.06 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,514 | $265.03 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,322 | $261.68 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 16,241 | $200.51 |
| 84702 | <1% | 18 | $170.24 | |
| 85027 | <1% | 1,497 | $138.67 | |
| 84466 | <1% | 12 | $105.84 | |
| 83690 | <1% | 2,667 | $102.51 | |
| 87328 | <1% | 15 | $90.48 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,183 | $88.51 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 446 | $65.80 |
| 83540 | <1% | 14 | $48.48 | |
| 80306 | <1% | 509 | $29.57 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 140 | $24.79 |
| 84703 | <1% | 528 | $22.71 | |
| 85610 | <1% | 309 | $5.56 | |
| 87329 | <1% | 15 | $3.48 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 502 | $2.56 |
| 81025 | 0% | 399 | $0.00 | |
| 71046 | Radiologic examination, chest; 2 views | 0% | 183 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 177 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 138 | $0.00 |
| 84100 | 0% | 13 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 14 | $0.00 |
| 82947 | 0% | 22 | $0.00 | |
| 36416 | 0% | 260 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 142 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 167 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 183 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 31 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 18 | $0.00 |
| A9270 | Non-covered item or service | 0% | 31 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialQUALLS, ALAN (CEO)
Parent organizationBANNER HEALTH
| Provider | Location | Paid |
|---|---|---|
| Banner Health | Fort Collins, CO | $1.04M |
| NCMC Specialty Clinic | Greeley, CO | $42K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.